‘Global Translational Regenerative Medicine Market Set To Grow To $61bn By 2022’ quotes a new Visiongain report

01 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Translational Regenerative Medicine Market Prospects 2018-2028: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

Regenerative medicine has been undergoing a period of sustained innovation over the last two decades. Tissue engineering and stem cell research in particular have seen a level of interest which it hasn’t received for a long while. Novel cell sources such as induced pluripotent stem cells have also helped to open new areas of research which had previously seemed impossible due to limited resources. There are potential opportunities in the market for participating companies, however certain risks and limitations also abound. The global regulations surrounding regenerative medicine remains fragmented. The changes to regulatory processes in the leading national and regional markets should help to drive progress in the regenerative medicine market.

The lead analyst of the report commented “Growth in the global translational regenerative medicine market will be fuelled particularly by stem cell therapies and tissue engineering advancements, as well as the emergence of commercial gene therapy products. The improvements in regulation of stem cell research on a regional level will increase its attractiveness. We note that advancements such as 3D bioprinting should enable the development of tissues which can be used for toxicology testing purposes.

Furthermore, strong government support for regenerative medicine particularly in countries such as China and South Korea, as well as the accelerated regulatory pathway for regenerative medicine in Japan will drive the growth in stem cell therapies.”

Leading companies featured in the report include Alphatec Spine, Anterogen, Athersys, Avita Medical, AxoGen, Medipost, Mesoblast, NuVasive, Ocata Therapeutics, Organogenesis, Pharmicell, Regenerys, TiGenix, UniQure, Vericel Corporation

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Biological Drug API Manufacturing market set to grow to $11bn by 2025” says Visiongain report

Strengths in the biotech contract manufacturing market, from the perspective of the CMOs, stem from the demand for lower cost manufacturing from companies of all sizes.

07 November 2019

Read

“global radiation oncology market is anticipated to surpass USD 6.5 billion by 2020”, says Visiongain

Growing aging population, urbanization, and growing wealth in low- and middle-income countries such as China and India are anticipated to boost the APAC radiation oncology market.

07 November 2019

Read

“Global Rabies Diagnostics Market is anticipated to surpass USD 1.8 billion by 2020”, says Visiongain

Several international healthcare organizations are working with healthcare organizations to develop and market new detection assays to drive efforts aimed at fighting the disease.

07 November 2019

Read

“Global spinal muscular atrophy (SMA) market is anticipated is to surpass USD 950 Million by 2020”, says Visiongain

Increasing awareness of SMA and increasing numbers of programs to expand treatment options for rare diseases are key factors that are boosting the market growth.

07 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever